The pharmacokinetics and penetration into a cantharidine-induced inflammatory exudate of meropenem was studied in six volunteers following a single 1-g intravenous dose. Concentrations in plasma, urine, and the inflammatory exudate were determined by a microbiological assay. The mean elimination half-life of meropenem in plasma was 1.1 h, with the concentration in plasma declining from a mean of 23.6 ,ug/ml at 1 h to 0.7 ,ug/mi at 6 h. The inflammatory fluid penetration was rapid (time to maximum concentration of drug in serum, 0.75 h), and the penetration was 111%. The recovery of meropenem in urine at 24 h was 65.4% of the administered dose.
Meropenem is a new carbapenem antimicrobial agent which shares with imipenem an a-hydroxyethyl at C-4 but differs in that it has a methyl group at C-1 and a dimethylcarbamoylpyrrolidinethio side chain at C-3 (8) . It is probable that the C-3 substituent accounts for the enhanced activity of this agent against gram-negative bacteria (3, 5) . Of considerable importance is the fact that studies in animals suggest that meropenem is relatively more stable to hydrolysis by the renal dehydropeptidase I (DHP-I) (3) than imipenem, and preliminary studies in humans confirm this stability, suggesting that a DHP-I enzyme inhibitor such as cilastatin is not necessary (1) . This property is probably associated with the methyl substituent at C4, as other agents with this structure have been associated with enhanced resistance to DHP-I (13) .
In this study we investigated the pharmacokinetics of meropenem in healthy volunteers, including the penetration of this agent into a chemically induced mild inflammatory exudate (14) . MATERIALS (2) to give a line of best fit for the standard curve. The lower limit of sensitivity of the assay was 0.1 ,ug/ml. Three internal controls were used; and the mean coefficients of variation of the assay between days were 6.3% at 0.4 ,ug/ml, 6.8% at 3.0 ,ug/ml, and 5.9% at 20 ,ug/ml.
Pharmacokinetic analysis of meropenem in serum was performed with the GPHARM program (4) by assuming a two-compartment model using the computational algorithm of peeling, with seven to eight points being fitted to the elimination phase. The structural model assumed a bolus injection. No corrections were applied for the 5-min infusion. Pharmacokinetic parameters for the inflammatory fluid were determined by standard graphical methods of individual volunteer data (12) . This included the area under the concentration-time curve (AUC), which was calculated by a log-linear trapezoidal rule procedure. The percent penetration of meropenem into inflammatory exudate was calculated by comparing the AUC from 0 h to infinity (AUC0,C) in inflammatory exudate with that in serum. Figure 1 depicts the levels of meropenem in plasma and inflammatory fluid following the 1,000-mg bolus injection, and Table 1 shows the derived pharmacokinetic data. The mean concentration in plasma at 0.25 h postdose was 55. 6 ,ug/ml (range, 43.7 to 66.5 ,ug/ml). Inspection of the pharmacokinetic profiles from the individual volunteers suggested that the distribution of meropenem was essentially complete by 1 h postdose, when the mean level in plasma was 23. 6 ,ug/ml (range, 19.6 to 26.9 ,ug/ml). Thereafter, there was a log-linear decline in the concentration in plasma with time to a mean of 0.7 ,ug/ml (range, 0.3 to 1.3 ,uglml) at 6 h. At 12 h the levels had fallen below the lower limit of sensitivity of the assay for all volunteers. The mean plasma elimination half-life of meropenem was 1.1 h, with a range of 0.9 to 1.4 h.
RESULTS
Penetration of meropenem into the inflammatory exudate was rapid, with the mean concentration at 0.5 h being 24.2 jxg/ml (range, 11.9 to 29.3 ,ug/ml), and the mean peak concentration was 28.3 ,ug/ml (range, 22.6 to 37.4 pug/ml) and was attained at 0.5 h in three volunteers and 1.0 h in the remaining three volunteers. The mean elimination half-life from the inflammatory exudate was 1.1 h. The mean percent The mean recovery of meropenem from the urine at 24 h was 65.4% (range, 52.0 to 73.0%) of the administered dose, with 62.3% being eliminated in the first 4 h. The mean total clearance of meropenem from the body was 253 ml/min (range, 208 to 329 ml/min), and the mean renal clearance was 182 ml/min (range, 131 to 241 ml/min).
Other than one volunteer with a headache, no adverse effects of meropenem were experienced by the volunteers and no alterations to biochemical or hematological parameters were found.
DISCUSSION
The pharmacokinetics of meropenem are broadly in agreement with those presented previously (1), with the exception that the recovery in urine reported by Bax et (1) .
There appear to be two major differences in the pharmacokinetics of meropenem and imipenem. The first is the higher urinary recovery of meropenem. In a similar study (with a different volunteer group) following a 500-mg injection of imipenem, a mean urinary recovery of 14.7% was found, which increased to 55.6% when imipenem was coadministered with an equal amount of cilastatin (7) . Hence, the recovery of meropenem exceeds that of imipenem even without the use of a DHP-I inhibitor. The second difference appears to be a possibly greater ability of meropenem, compared with that of imipenem, to penetrate tissues. By a similar method of analysis, the percent penetration of imi-A .I penem into inflammatory fluid was 67.8 ± 13.8% (standard deviation) when given with inhibitor and 73.2 ± 13.9% (standard deviation) when given alone (7) . The penetration of meropenem was 110.0 ± 15.6% (standard deviation). Meropenem also compares favorably in this respect when it is compared with cefepime (penetration, 80.4%) (10) and the penem FCE 22101 (penetration, 60.9%) (11) . However, crossover studies should be performed to confirm these findings. The suggestion that meropenem penetrates tissue efficiently is further supported by the finding that the volume of distribution of this compound (20.6 liters) is greater than those of other P-lactams, for example, cefepime (13.6 liters) (10), FCE 22101 (16.6 liters) (11) , and imipenem (16.7 liters) (as calculated from the data of Norrby et al. [9] ). However, it is possible that the high degree of penetration reported here for meropenem might be an overestimate related to one outlier result of 130.4%. If this result were ignored, the mean percent penetration would be 100.4%.
The rapidity of penetration of meropenem into inflammatory fluid is also noteworthy, in that maximum levels were attained by 0.5 h in one-half of the volunteers and by 1 h in all volunteers. In this respect meropenem resembles imipenem (7).
Meropenem has a high level of activity against a wide range of bacterial pathogens. Members of the family Enterobacteriaceae, Staphylococcus spp. (other than methicillinresistant strains), and Bacteroides fragilis are inhibited by low concentrations (MIC for 90% of strains, s0.25 ,ug/ml) (6). These results therefore suggest that a twice-daily dosing of 1 g might be sufficient to treat these pathogens. Pseudomonas aeruginosa (MIC for 90% of strains, 4 ,ug/ml) might require a larger dose or more frequent dosing. Clinical trials to support these observations are warranted.
